Clever Culture Systems (ASX: CC5) reported continued commercial progress for its APAS® Independence technology, completing three sales to existing customers Novo and AstraZeneca during the first quarter of FY27. All three instruments were fully invoiced during the quarter. The Adelaide-based AI microbiology automation company also outlined expectations for sales and new evaluation commitments totalling eight units in the first half of FY27, matching the eight units sold to pharmaceutical customers across the full FY26 financial year.
The company reported progress in its pharmaceutical sales pipeline, with two existing global pharmaceutical customers expected to complete their evaluations and proceed to purchases during the December quarter. A new top-20 global pharmaceutical company is also expected to commence a paid APAS evaluation, potentially expanding the company’s engagement with major pharmaceutical manufacturers to nine. Clever Culture Systems is also finalising a purchase commitment with a single-site pharmaceutical manufacturer, while its recently announced partnership with PSC Biotech provides an additional commercial sales channel and includes a commitment to purchase an APAS instrument.
CEO and Managing Director Brent Barnes said the company’s focus remained on converting evaluations into purchases and supporting broader deployments across customers’ manufacturing networks. Customer presentations from AstraZeneca and CSL also reinforced the potential for APAS technology to improve laboratory processes and support wider adoption. Clever Culture Systems continues to pursue its strategy of expanding initial installations into multi-site deployments, with the aim of increasing its global installed base and recurring software revenue. The company noted that the timing of sales conversions may vary, with anticipated orders subject to final customer decisions.
Click here to view the full ASX announcement.
